Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more
Esperion Therapeutics Inc - Asset Resilience Ratio
Esperion Therapeutics Inc (ESPR) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2023)
This chart shows how Esperion Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Esperion Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Esperion Therapeutics Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Esperion Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Esperion Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Esperion Therapeutics Inc (2002–2023)
The table below shows the annual Asset Resilience Ratio data for Esperion Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $205.80 Million | -- |
| 2022-12-31 | 16.97% | $42.09 Million | $247.94 Million | +3.76pp |
| 2021-12-31 | 13.22% | $50.44 Million | $381.59 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $353.26 Million | -- |
| 2019-12-31 | 16.16% | $34.65 Million | $214.45 Million | -52.89pp |
| 2018-12-31 | 69.05% | $99.05 Million | $143.45 Million | +9.40pp |
| 2017-12-31 | 59.65% | $165.73 Million | $277.83 Million | -11.07pp |
| 2016-12-31 | 70.72% | $173.42 Million | $245.21 Million | +25.07pp |
| 2015-12-31 | 45.65% | $134.93 Million | $295.57 Million | +31.14pp |
| 2014-12-31 | 14.51% | $20.80 Million | $143.34 Million | +10.01pp |
| 2013-12-31 | 4.50% | $3.53 Million | $78.29 Million | -3.97pp |
| 2002-12-31 | 8.47% | $4.35 Million | $51.41 Million | -- |